These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 9916110

  • 1. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice.
    Hu MS, Schwartzman JD, Yeaman GR, Collins J, Seguin R, Khan IA, Kasper LH.
    Infect Immun; 1999 Feb; 67(2):928-35. PubMed ID: 9916110
    [Abstract] [Full Text] [Related]

  • 2. Involvement of apoptosis and interferon-gamma in murine toxoplasmosis.
    Shen DF, Matteson DM, Tuaillon N, Suedekum BK, Buggage RR, Chan CC.
    Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2031-6. PubMed ID: 11481268
    [Abstract] [Full Text] [Related]

  • 3. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
    Fecho K, Cohen PL.
    J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
    [Abstract] [Full Text] [Related]

  • 4. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.
    Rich RF, Green WR.
    J Virol; 1999 May; 73(5):3826-34. PubMed ID: 10196277
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
    Kim S, Kim KA, Hwang DY, Lee TH, Kayagaki N, Yagita H, Lee MS.
    J Immunol; 2000 Mar 15; 164(6):2931-6. PubMed ID: 10706679
    [Abstract] [Full Text] [Related]

  • 8. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
    Wahlsten JL, Gitchell HL, Chan CC, Wiggert B, Caspi RR.
    J Immunol; 2000 Nov 15; 165(10):5480-6. PubMed ID: 11067900
    [Abstract] [Full Text] [Related]

  • 9. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR.
    J Immunol; 2002 Sep 01; 169(5):2727-35. PubMed ID: 12193747
    [Abstract] [Full Text] [Related]

  • 10. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
    Fleck M, Zhang HG, Kern ER, Hsu HC, Müller-Ladner U, Mountz JD.
    Arthritis Rheum; 2001 Apr 01; 44(4):964-73. PubMed ID: 11315936
    [Abstract] [Full Text] [Related]

  • 11. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A, Odorico JS.
    Transplantation; 1998 Dec 27; 66(12):1793-801. PubMed ID: 9884278
    [Abstract] [Full Text] [Related]

  • 12. Fas ligand is required for resolution of granulomatous experimental autoimmune thyroiditis.
    Wei Y, Chen K, Sharp GC, Braley-Mullen H.
    J Immunol; 2004 Dec 15; 173(12):7615-21. PubMed ID: 15585889
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cells in the pathogenesis of murine ocular toxoplasmosis.
    Lu F, Huang S, Kasper LH.
    Infect Immun; 2004 Sep 15; 72(9):4966-72. PubMed ID: 15321988
    [Abstract] [Full Text] [Related]

  • 14. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
    Fecho K, Bentley SA, Cohen PL.
    Cell Immunol; 1998 Aug 25; 188(1):19-32. PubMed ID: 9743554
    [Abstract] [Full Text] [Related]

  • 15. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
    Davidson WF, Haudenschild C, Kwon J, Williams MS.
    J Immunol; 2002 Dec 01; 169(11):6218-30. PubMed ID: 12444127
    [Abstract] [Full Text] [Related]

  • 16. The role of Fas-FasL in the development and treatment of ischemic retinopathy.
    Barreiro R, Schadlu R, Herndon J, Kaplan HJ, Ferguson TA.
    Invest Ophthalmol Vis Sci; 2003 Mar 01; 44(3):1282-6. PubMed ID: 12601060
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
    Shimizu M, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A.
    Cancer Immunol Immunother; 1998 Nov 01; 47(3):143-8. PubMed ID: 9829839
    [Abstract] [Full Text] [Related]

  • 18. FasL-Fas interactions regulate neovascularization in the cornea.
    Stuart PM, Pan F, Plambeck S, Ferguson TA.
    Invest Ophthalmol Vis Sci; 2003 Jan 01; 44(1):93-8. PubMed ID: 12506060
    [Abstract] [Full Text] [Related]

  • 19. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
    Priceputu E, Rodrigue I, Chrobak P, Poudrier J, Mak TW, Hanna Z, Hu C, Kay DG, Jolicoeur P.
    J Virol; 2005 May 01; 79(10):6377-91. PubMed ID: 15858021
    [Abstract] [Full Text] [Related]

  • 20. Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver.
    Lombard C, McKallip RJ, Hylemon PB, Nagarkatti PS, Nagarkatti M.
    Clin Immunol; 2003 Nov 01; 109(2):144-53. PubMed ID: 14597213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.